A Study of Laquinimod Eye-drops in Healthy Participants

• Status: Recruiting
• Trial end date: 2022-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a Phase 1 randomized, double-masked, placebo-controlled study performed with healthy participants to assess the safety and tolerability of laquinimod eye-drops.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Active Biotech AB

Criteria

Main inclusion criteria:

• In good health according to medical history, physical examination, vital signs, ECG and clinical chemistry, urinary and hematological laboratory tests

Main exclusion criteria:

• Unable or unwilling to use eye-drops

• Current usage of contact lenses

• History of eye surgery

• Sign or symptom of active eye disease

• History of an eye disease or other condition that could interfere with eye examinations in the study, or with ocular absorption of the investigational product

• History of inflammatory ocular disease

• History of cardiovascular or pulmonary disorder

• Family history of known or suspected hereditary cardiovascular disease

• Autoimmune disease or known family history of autoimmune disease

• Any other condition that would contraindicate subject's participation in the clinical study due to safety concerns or compliance with clinical study procedures